Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | PTPRC | P08575 | 2/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | S100A4 | P26447 | 1/20 | 0.39 |
| ▸ | IKBKB | O14920 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.39 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28883292 | 0.80 | HTR7 (0.46) | HTR7ALDH1A1LMNAIDO1SCN2A | |
| SCHEMBL29687996 | 0.79 | CYP3A4 (0.48) | ALDH1A1MAPK1TDP1HPGDPTGS2 | |
| SCHEMBL185120 | 0.79 | CYP3A4 (0.48) | ALDH1A1MAPK1TDP1HPGDPTGS2 | |
| SCHEMBL8202301 | 0.78 | ALDH1A1 (0.47) | HTR7ALDH1A1LMNAIDO1SCN2A | |
| SCHEMBL29770893 | 0.78 | CYP3A4 (0.44) | ALDH1A1MAPK1TDP1TSHRHPGD | |
| SCHEMBL692232 | 0.78 | CYP3A4 (0.44) | ALDH1A1MAPK1TDP1TSHRHPGD | |
| SCHEMBL27685518 | 0.77 | HTR7 (0.43) | HTR7ALDH1A1LMNAIDO1SCN2A | |
| Methane SCHEMBL27501832 | 0.77 | CYP3A4 (0.47) | ALDH1A1MAPK1TDP1HPGDPTGS2 | |
| SCHEMBL28240316 | 0.77 | ALDH1A1 (0.58) | HTR7ALDH1A1LMNASCN2APOLB | |
| SCHEMBL27993066 | 0.76 | CASP3 (0.62) | HTR7ALDH1A1LMNAIDO1SCN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2284157-A1 | Quinolines useful in treating cardiovascular disease | Wyeth (US) | 2011-02-16 | — | — | EP | disclosed |
| US-7576215-B2 | Quinolines and pharmaceutical compositions thereof | WYETH (US) | 2009-08-18 | — | — | US | disclosed |
| EP-1692111-A2 | QUINOLINES USEFUL IN TREATING CARDIOVASCULAR DISEASE | Wyeth, A Corporation of the State of Delaware (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20060166866-A1 | Cell adhesion inhibitors | BIOGEN, INC., A MASSACHUSETTS CORPORATION | 2006-07-27 | — | — | US | disclosed |
| WO-2005058834-A2 | QUINOLINES USEFUL IN TREATING CARDIOVASCULAR DISEASE | WYETH (US) | 2005-06-30 | — | — | WO | disclosed |
| US-20050131014-A1 | Quinolines useful in treating cardiovascular disease | WYETH (US) | 2005-06-16 | — | — | US | disclosed |
| US-6630512-B2 | Antiinflammatory agents; autoimmune disease | BIOGEN, INC. | 2003-10-07 | — | — | US | disclosed |
| US-20030018016-A1 | Cell adhesion inhibitors | BIOGEN IDEC MA, INC. | 2003-01-23 | — | — | US | disclosed |
| US-6376538-B1 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASES | BIOGEN, INC. | 2002-04-23 | — | — | US | disclosed |
| EP-1142867-A2 | Cell adhesion inhibitors | BIOGEN, INC. (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-0805796-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1997-11-12 | — | — | EP | disclosed |
| WO-1996022966-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1996-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166866-A1 | Cell adhesion inhibitors | ICAM1, VCAM1, EPCAM | HTR7 3654/4885ALDH1A1 450/4885LMNA 2271/4885 |
| US-20050131014-A1 | Quinolines useful in treating cardiovascular disease | NR1H2, NR1H3, SREBF1 | HTR7 1188/4885ALDH1A1 1202/4885LMNA 1278/4885 |
| US-20030018016-A1 | Cell adhesion inhibitors | ICAM1, VCAM1, EPCAM | HTR7 3654/4885ALDH1A1 450/4885LMNA 2271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.